Advanced

Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease

Davidsson, P; Blennow, K; Andreasen, N; Eriksson, B; Minthon, Lennart LU and Hesse, C (2001) In Neuroscience Letters 300(3). p.157-160
Abstract
The clinical significance and the effects of pharmacological treatment of patients with Alzheimer's disease (AD) were evaluated by measurement of acetylcholinesterase (AChE) in the cerebrospinal fluid (CSF). CSF-AChE of AD patients was lower, not significantly, compared with controls. However, CSF-AChE was significantly increased after treatment of AD patients with AChE inhibitors (donepezil and galantamine). The increase was higher in patients treated with donezepil than in those treated with galantamine, which might be related to different mechanisms for the substances. The increase was also dose-dependent, and was especially marked in patients showing a clinical response. These data suggest that CSF biomarkers are capable not only of... (More)
The clinical significance and the effects of pharmacological treatment of patients with Alzheimer's disease (AD) were evaluated by measurement of acetylcholinesterase (AChE) in the cerebrospinal fluid (CSF). CSF-AChE of AD patients was lower, not significantly, compared with controls. However, CSF-AChE was significantly increased after treatment of AD patients with AChE inhibitors (donepezil and galantamine). The increase was higher in patients treated with donezepil than in those treated with galantamine, which might be related to different mechanisms for the substances. The increase was also dose-dependent, and was especially marked in patients showing a clinical response. These data suggest that CSF biomarkers are capable not only of identifying a biochemical effect of drugs, but also of differentiating between different compounds in a dose-dependent manner. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Neuroscience Letters
volume
300
issue
3
pages
157 - 160
publisher
Elsevier
external identifiers
  • wos:000167443400008
  • scopus:0035896466
ISSN
0304-3940
DOI
10.1016/S0304-3940(01)01586-5
language
English
LU publication?
yes
id
3a6f1c2b-1397-406f-ab4e-348598bf46f3 (old id 1297309)
date added to LUP
2009-07-15 10:21:48
date last changed
2018-01-07 06:17:23
@article{3a6f1c2b-1397-406f-ab4e-348598bf46f3,
  abstract     = {The clinical significance and the effects of pharmacological treatment of patients with Alzheimer's disease (AD) were evaluated by measurement of acetylcholinesterase (AChE) in the cerebrospinal fluid (CSF). CSF-AChE of AD patients was lower, not significantly, compared with controls. However, CSF-AChE was significantly increased after treatment of AD patients with AChE inhibitors (donepezil and galantamine). The increase was higher in patients treated with donezepil than in those treated with galantamine, which might be related to different mechanisms for the substances. The increase was also dose-dependent, and was especially marked in patients showing a clinical response. These data suggest that CSF biomarkers are capable not only of identifying a biochemical effect of drugs, but also of differentiating between different compounds in a dose-dependent manner.},
  author       = {Davidsson, P and Blennow, K and Andreasen, N and Eriksson, B and Minthon, Lennart and Hesse, C},
  issn         = {0304-3940},
  language     = {eng},
  number       = {3},
  pages        = {157--160},
  publisher    = {Elsevier},
  series       = {Neuroscience Letters},
  title        = {Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease},
  url          = {http://dx.doi.org/10.1016/S0304-3940(01)01586-5},
  volume       = {300},
  year         = {2001},
}